TAK-390MR Phase 3 Data Presented At Digestive Disease Week

TAP Pharmaceutical Products Inc. have reported results from three pivotal Phase 3 studies evaluating investigational new drug TAK-390MR, the first proton pump inhibitor (PPI) with an innovative dual delayed release technology, in healing patients with erosive esophagitis (EE) and in maintenance of healed EE. ...

Write comment to this article:

Subject:

Name:

email or site:

Code: